Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress

Ascendis Pharma (NasdaqGS:ASND) is back in focus after Canada’s Drug Agency recommended conditional public reimbursement for Yorvipath, its parathyroid hormone replacement for adults with chronic hypoparathyroidism whose symptoms are not adequately managed on conventional therapy.

That backdrop helps explain why Ascendis Pharma’s recent momentum has picked up. The stock’s 90 day share price return of 28.56% and year to date share price return of 10.26%, alongside legal clarity around Yuviwel and progress on Yorvipath access, point to improving sentiment rather than fading enthusiasm.

Capitalize on the renewed interest in Ascendis Pharma by reviewing a curated shortlist of other health focused companies in our list of solid balance sheet and fundamentals (52 results).

After a 28.56% move over 90 days, Ascendis Pharma now trades at about $270.56, while analyst targets cluster near $314 and intrinsic value estimates suggest a much wider gap. Is the market still underpricing this story, or already being generous?

Most Popular Narrative: 14% Undervalued

Ascendis Pharma’s most followed narrative puts fair value at about $313 per share, compared with the recent $270.56 close. This gives that story clear room to work with.

Expansion of SKYTROFA into additional established growth hormone indications such as ISS, SHOX deficiency, Turner syndrome and SGA, alongside potential use in new segments like achondroplasia, can increase total addressable demand and contribute to higher revenue and more efficient use of existing commercial infrastructure.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value sits well above today’s price? The narrative discusses revenue expansion, margins, and a richer earnings multiple. Curious which assumptions really carry the model and how the discount rate shapes that $313 figure?

Result: Fair Value of $313 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Ascendis Pharma narrative also relies on Yorvipath sustaining its trajectory and Yuviwel meeting high launch expectations, so any slowdown there could quickly challenge the current valuation story.

Find out about the key risks to this Ascendis Pharma narrative.

Next Steps

Mixed signals around Ascendis Pharma can create strong views on both sides. Move quickly, review the evidence yourself, and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Ascendis Pharma?

If Ascendis Pharma has your attention, do not stop there. Use the Simply Wall Street Screener to uncover other stocks that could fit your portfolio and risk appetite.

• Target potential mispricing by reviewing companies that appear to trade below their estimated value with the help of 47 high quality undervalued stocks.
• Prioritise resilience and sleep a little easier at night by focusing on 82 resilient stocks with low risk scores.
• Spot opportunities before the crowd by scanning through 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com